Pharmalink AB, a specialty pharmaceutical company focused on orphan and niche products, has raised SEK96 million ($15 million) in Series C financing led by Investinor and Industrifonden. The company previously raised SEK35 million ($5.46 million) in 2012.
The new funds will be used to:
• Prepare for pivotal studies of Busulipo, a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation
• Complete the pivotal Phase IIb study of Nefecon, a potential disease-modifying treatment for patients with primary IgA nephropathy
• Seek commercial partners for its products outside the Nordic region and facilitate in-licensing or acquisition of additional opportunities for commercialization in the Nordic region
Both products are expected to complete pivotal studies in 2015.